Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Feb;55(4):495-496.
doi: 10.1111/apt.16767.

Editorial: safety of ustekinumab in pregnancy-are we there yet?

Affiliations
Editorial

Editorial: safety of ustekinumab in pregnancy-are we there yet?

Caecilie Skejø et al. Aliment Pharmacol Ther. 2022 Feb.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. van der Woude CJ, Ardizzone S, Bengtson MB, et al. The second European evidenced-based consensus on reproduction and pregnancy in inflammatory bowel disease. J Crohns Colitis. 2015;9:107-124.
    1. Mahadevan U, Long MD, Kane SV, et al. Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease. Gastroenterology. 2021;160:1131-1139.
    1. Kane SV, Acquah LA. Placental transport of immunoglobulins: a clinical review for gastroenterologists who prescribe therapeutic monoclonal antibodies to women during conception and pregnancy. Am J Gastroenterol. 2009;104:228-233.
    1. Flanagan E, Gibson PR, Wright EK, et al. Infliximab, adalimumab and vedolizumab concentrations across pregnancy and vedolizumab concentrations in infants following intrauterine exposure. Aliment Pharmacol Ther. 2020;52:1551-1562.
    1. Grišić A-M, Dorn-Rasmussen M, Ungar B, et al. Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease. United European Gastroenterol J. 2021;9:91-101.

Substances

LinkOut - more resources